Posted by Michael Wonder on 16 Feb 2018
Pfizer receives breakthrough therapy designation from FDA for PF-04965842, an oral JAK1 inhibitor, for the treatment of patients with moderate-to-severe atopic dermatitis
14 February 2018 - Pfizer today announced its once-daily oral Janus kinase 1 (JAK1) inhibitor PF-04965842 received breakthrough therapy designation from the U.S. FDA for the treatment of patients with moderate-to-severe atopic dermatitis.
The Phase 3 program for PF-04965842 initiated in December and is the first trial in the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) global development program.
